Monte Rosa Triggers $50M Milestone as Novartis Starts Phase 2 Sjögren's Study
GLUE has more than doubled off its 52-week low of $4.79.
Summary
Novartis initiated a Phase 2 study of MRT-6160 in Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa under their global license agreement.
Key Events · Product Development and Regulatory · GLUE
-
Phase 2 Initiation Triggers $50M Milestone
Novartis initiated a Phase 2a/b study of MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa.
-
Up to $2.1B in Total Milestones
Under the Novartis Agreement, Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, beginning with Phase 2 initiations.
-
Non-Dilutive Cash Addition
The $50 million payment adds to Monte Rosa's $626 million cash position, which already funds operations into 2029.
-
First of Several Planned Phase 2 Studies
Additional Phase 2 studies are expected across immune-mediated diseases, with Monte Rosa eligible for additional initiation milestones.
Analysis · GLUE · Life Sciences
Novartis has initiated the first Phase 2 study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa. This is the first of several planned Phase 2 studies under the global license agreement, which carries up to $2.1 billion in total milestones. The payment adds non-dilutive cash to a balance sheet that already holds $626 million, extending runway into 2029. The milestone validates the VAV1-directed molecular glue degrader platform and moves the lead partnered asset into mid-stage development.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLUE was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.79 to $25.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.